Kimberly R. Spoerri
Partner
“Kim is incredibly responsive and can be counted on for top-level advice and a 360-degree view of a situation.”
Chambers USA
“She is extremely responsive, attentive and right to the point. If any issues come up, she clearly presents the solutions.”
Chambers USA
Rising Star: Mergers and Acquisitions
Law360, 2023
Top Women in M&A Dealmaking
The Deal, 2023, 2021
Kimberly Spoerri’s practice focuses on advising corporate clients in connection with all aspects of their domestic and cross-border M&A activities and corporate governance and activism matters.
Kim has significant experience with acquisitions and divestitures of public and private entities, joint ventures, carve-out transactions, spin-offs and RMTs, and other complex corporate transactions.
Kim joined the firm in 2008 and became partner in 2017.
Notable Experience
Pharmaceuticals and Health Care Experience
-
Asahi Kasei in its $1.1 billion acquisition of Calliditas Therapeutics.
-
Ecolab in the $950 million sale of its surgical solutions business to Medline.
-
GlaxoSmithKline in its $1.4 billion acquisition of Aiolos, its $1.9 billion acquisition of Sierra Oncology, its unsolicited tender offer to acquire Human Genome Sciences and the resulting negotiated acquisition for $3.6 billion, and its $2.9 billion acquisition of Steifel Laboratories.
-
Takeda in its up to $6 billion acquisition of NDI-034858 from Nimbus Therapeutics, its $5.2 billion acquisition of ARIAD Pharmaceuticals, and its agreement with Ovid to secure global rights to, and assume sole responsibility for, the further worldwide development and commercialization of the investigational medicine soticlestat.
-
Shionogi in its acquisition of Qpex Biopharma Inc., a clinical stage pharmaceutical company with expertise in antimicrobial research and development.
-
Altaris Capital Partners in its acquisition of a 51% stake in Solesis and its acquisition of the Johnson Matthey Health Business.
-
MSD Animal Health, the global animal health division of Merck & Co., in its acquisition of rights for Vecoxan from Elanco Animal Incorporated.
-
Henry Schein in its Reverse Morris Trust transaction in which Henry Schein spun-off its Animal Health business and merged it with Vets First Choice to form Covetrus, a new publicly traded company.
-
Merck & Co. in its joint venture with Sanofi Pasteur for the exploitation of hexavalent vaccine Vaxelis.
-
Allergan in its proposed $160 billion merger with Pfizer.
Technology, Media, and Telecommunications Experience
-
American Tower in its sale of an approximately 29% ownership interest and $570 million follow-on sale of additional interests in its U.S. data center business to Stonepeak, its $10.1 billion acquisition of CoreSite, its $3.5 billion acquisition of InSite, and $5 billion acquisition of over 11,000 wireless communications towers from Verizon.
-
Google in a variety of transactions, including its acquisitions of cwist, Orbitera, Waze, and Motorola Mobility.
-
The Raine Group and Temasek in an investment in SoundCloud.
-
Lenovo in its $2.3 billion acquisition of IBM’s x86 server business.
-
The Home Depot in its acquisition of BlackLocus and Redbeacon.
Retail/Consumer Experience
-
Keurig Dr Pepper in its pending acquisition of GHOST.
-
American Express in numerous transactions, including its sale of Accertify to Accel-KKR, American Express Global Business Travel’s business combination with Apollo Strategic Growth Capital and in various co-branded credit card arrangements, including its small business co-branded credit card agreement with Amazon and its co-branded credit card agreement with Marriott.
-
Tempur Sealy International in its $4 billion announced acquisition of Mattress Firm Group.
-
FullBeauty Brands in its acquisition of certain assets and assumption of certain liabilities of Eloquii Design from Walmart.
-
Bed Bath & Beyond in its negotiated cooperation agreement with RC Ventures.
-
GiVi Holding (the Versace Family holding company of Gianni Versace S.p.A.) and Donatella Versace in the $2.13 billion sale of Versace to Michael Kors Holdings.
-
Couche-Tard in its acquisition of Holiday Stationstores.
-
CJ CheilJedang in its $1.8 billion acquisition of Schwan’s Co.
Industrials and Manufacturing Experience
-
Johnson Controls in the sale of its Air Distribution Technologies business to Truelink Capital, its acquisition of workplace management software leader FM:Systems, and in its $870 million acquisition of Silent-Aire.
-
Honeywell in its spin-offs of Resideo Technologies and Garrett Motion, and in connection with its $1.325 billion buyout agreement with the North American Refractories Asbestos Personal Injury Settlement Trust.
-
BHP Copper, a subsidiary of BHP Billiton, in the sale of its Pinto Valley copper mining operations and the San Manuel Arizona Railroad Company to Capstone Mining.
Other Select Experience
-
MDC in its business combination transaction with Stagwell.
-
iCapital Network in its acquisition of Wells Fargo’s feeder fund platform business.
-
Warburg Pincus in its acquisition of Electronic Funds Source and the subsequent sale of EFS to WEX.
-
Genting Hong Kong as a shareholder of Norwegian Cruise Line in NCL’s $3 billion acquisition of Prestige Cruises International.
-
OneWest Bank in its $3.4 billion sale to CIT Group.
-
Pluspetrol Resources Corp. in its acquisition of Apco Oil and Gas International and in its acquisition of substantially all of the assets of Harvest Natural Resources.
-
Conversus Capital in the $1.4 billion sale of its portfolio of third-party private equity fund interests to HarbourVest Partners.
Selected Activities
triggerSenior Executive Editor, Law Review, New York University School of Law
Publications
-
Cleary's Pharma Bites: Contingent Value Rights (CVRs) in Pharmaceutical Deals
-
The SEC’s Proposed Changes to Beneficial Ownership Reporting
-
Cleary’s Pharma Bites: Contingent Value Rights (CVRs) in Pharmaceutical Deals
-
Risks to the Buyer of Fiduciary Duty Breaches by the Target in the M&A Sale Process
-
Companies Enacting ‘Weinstein Clause’ In Wake Of #MeToo Movement
-
Cleary Partners Participate in Panel Discussion on Board Oversight of Sexual Harassment
Events
-
October 10, 2024
-
November 9, 2023
-
October 5, 2023
-
October 6, 2022
-
March 4, 2020
-
October 10, 2019
-
October 4, 2018
-
May 23, 2018
-
March 13, 2018
The Conference Board’s Why Board Oversight Is Critical in Helping Stop Harassment
-
March 6, 2018